ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
23 hedge funds and large institutions have $601K invested in ImmunoCellular Therapeutics, Ltd. in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
105% more capital invested
Capital invested by funds: $293K → $601K (+$308K)
35% more funds holding
Funds holding: 17 → 23 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$119K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$109K |
| 3 |
Millennium Management
New York
|
+$104K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$18.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$3K |
IMUC Hedge Fund Activity: Q1 2018 in Review
23 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q1 2018, worth a combined $601K — up 105% from $293K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IMUC positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $119K. The largest seller was Goldman Sachs, exiting entirely with an estimated $8K sold.
- 23 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q1 2018, up from 17 in Q4 2017.
- Funds reported $601K of ImmunoCellular Therapeutics, Ltd. stock for Q1 2018, up 105% quarter-over-quarter.
- 8 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q1 2018 and 2 closed out, a net change of +6 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q1 2018 was Renaissance Technologies, an estimated $119K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q1 2018 was Goldman Sachs, an estimated $8K sold.
Based on aggregated 13F filings for Q1 2018.